BEC is a leading manufacturer of biomedical testing instrument systems, tests and supplies
that simplify and automate processes in the clinical lab and life sciences research settings. A
majority of revenue comes from reagent test kits, supplies and services. The company has
sales in more than 130 countries and roughly 10,500 employees worldwide.
Roughly 83% of revenue is derived from sales to clinical labs, of which more than 90% is
recurring revenue from supplies, test kits, services and operating-type lease payments.
Central laboratories of mid- to large-size hospitals represent the company’s most significant
customer group.
[edit] Corporate Overview
[edit] History
[edit] Business Financials
Revenue and Net Income (2005-7)
[1][edit] Major Product Segments
[edit] Trends and Forces
[edit] Competition
Becton, Dickinson and Company (BDX),
Abbott Laboratories (ABT),
JOHNSON & JOHNSON (JNJ),
Roche Pharmaceuticals (RHHBY),
Siemens AG (SI)
| Income Data, in millions USD | Beckman Coulter | Abbott Laboratories (ABT) | Roche Diagnostics | JOHNSON & JOHNSON (JNJ) | Becton, Dickinson and Company (BDX) | Siemens AG (SI)
|
| 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006
|
| Net revenue | $2,761 | $2,528 | $25,914 | $22,476 | $9,350 | $8,747 | $61,095 | $53,324 | $6,360 | $5,738 | $72,448 | $66,487
|
| Net income | $211.3 | $186.9 | $3,606 | $1,716 | $1,648 | $1,422 | $10,576 | $11,053 | $890.0 | $752.3 | $2,417 | $3,043
|
| R&D as % of sales | 9.9% | 10.5% | 9.7% | 10% | 8.4% | 8.0% | 12.6% | 13.4% | 5.7% | 5.3% | 4.7% | 4.6%
|
| Return on Assets | 5.9% | 5.7% | 9.1% | 4.7% | N/A | N/A | 13.1% | 15.7% | 12.1% | 11.0% | 2.6% | 3.5%
|
| Return on Equity | 14.7% | 16.2% | 20.3% | 12.2% | N/A | N/A | 24.4% | 28.1% | 20.4% | 19.6% | 8.3% | 12.1%
|
[edit] References
- ↑ Beckman Coulter (BEC) Form 10-K, Fiscal year 2007, p. 32
Edit Metric
Edit
History
Bookmark
